[Short and long-term therapeutic effects of rapamycin-eluting stent and paclitaxel-eluting stent in treatment of coronary disease with complicated lesions].
OBJECTIVE
To compare the short and long-term clinical outcomes of rapamycin (sirolimus)-eluting stent (DES) (CYPHER stent) and paclitaxel-DES (TAXUS stent) in treatment of coronary heart disease (CHD) patients with complicated lesions.


METHODS
611 CHD patients with 642 lesions, were treated with 698 CYPHER stents, and 450 sex, age, clinical data and lesion type-matched patients, with 534 lesions, were treated with 600 TAXUS stents by means of percutaneous coronary intervention. The short and long term outcomes were compared between these 2 groups.


RESULTS
The success rate of stent implantation was 99.2% (606/611) and 98.8% (445/450) in the CYPHER stent and TAXUS stent groups respectfully. The overall rate of major cardiac events, including death, acute myocardial infarction (AMI) target lesion revascularization (TLR), and major adverse cardiac event (MACE), during hospitalization and 6 - 8 month' follow-up were 0.65% and 2.3% in the CYPHER stent group, not significantly different from those of the TAXUS stent group (1.3% and 3.2% respectively). The restenosis rate of the TAXUS stent group was 7.3%, a little higher than that of the CYPHER stent group (14%), but without significant difference.


CONCLUSIONS
CYPHER and TAXUS DES are both safe and effective in CHD patients with complicated lesions. There is an increasing tendency of restenosis rate in the TAXUS stent group in comparison with the CYPHER stent.
Chen
Ji-lin
JL
Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing 100037, China.
Gao
Run-lin
RL
Yang
Yue-jin
YJ
Qiao
Shu-bin
SB
Qin
Xue-wen
XW
Yao
Min
M
Liu
Hai-bo
HB
Xu
Bo
B
Wu
Yong-jian
YJ
Yuan
Jin-qing
JQ
Chen
Jue
J
Dai
Jun
J
You
Shi-jie
SJ
Ma
Wei-hua
WH
D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D003327:Coronary Disease / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome
D017239:Paclitaxel; D020123:Sirolimus